novavax vaccine - Search News

Order byBest matchMost fresh

Novavax scores narrower Covid vaccine approval

Top News

Overview

Impacts

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

· 3d · on MSN

· 5d · on MSN

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk

STAT · 5h

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

The FDA plans to limit access to covid vaccines. Here’s why that’s not all bad.

Covid vaccines will soon be required to go through more rigorous trials to ensure that they really are beneficial for people who aren’t at high risk.

MIT Technology Review · 12h

· 1d

FDA panel recommends keeping COVID shots targeted to same strain as last year

· 1d

FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

Public health experts say that there is no certainty on which strains are going to be dominant.

· 1d

· 6h

COVID shots should target newer strains of JN.1 variant, US FDA advisers say

· 22h

With vaccine approval process set to change, FDA advisers leave wiggle room in annual Covid-19 shot recommendations

BioPharma Dive4d

Novavax’s COVID vaccine gets FDA approval, but with limits

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the company.

4don MSN

FDA approves Novavax COVID vaccine with new conditions

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House of Representatives try to overcome internal divisions about cuts to the Medicaid health program and tax breaks in high-cost coastal states.

Trump’s FDA just changed COVID vaccine rules for 2025 — will you still qualify for boosters under the new guidelines?

FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and high-risk individuals. While the FDA met to decide if vaccine formulas should change for fall 2025,

JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,

Explore more

Covid

Food and Drug Administration

Helen Branswell